Diuretics are the first-line medical treatment for ascites caused by liver cirrhosis, and they work in the majority of patients when combined with dietary sodium restriction. The standard regimen pairs spironolactone with furosemide, targeting the hormonal imbalance that drives the kidneys to hold onto salt and water. Yet diuretics alone don’t tell the whole story of ascites management. Roughly one in ten patients eventually stops responding to them, and how and when diuretics are monitored matters as much as which ones are prescribed.
Why Fluid Accumulates in the Abdomen
Ascites in cirrhosis isn’t simply “too much fluid.” It results from a cascade that starts with scarring in the liver, which raises pressure in the portal vein. That elevated portal pressure triggers the blood vessels feeding the gut and spleen to widen, a process called splanchnic vasodilation. The widening is driven by a surge in local vasodilators and a reduced responsiveness to the body’s usual vessel-tightening signals.1PubMed Central. Physiopathology of splanchnic vasodilation in portal hypertension This vasodilation simultaneously worsens portal pressure by increasing the volume of blood flowing into an already congested portal system.2PubMed Central. Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis
From the body’s perspective, all that blood pooling in the splanchnic vessels makes the arterial system feel underfilled. The kidneys respond as if you were dehydrated: they activate the renin-angiotensin-aldosterone system (RAAS) and hold onto sodium aggressively.3PubMed. Mechanisms of ascites formation That retained sodium pulls water along with it. Meanwhile, the high pressure inside the liver’s blood vessels pushes lymph fluid out into the abdominal cavity faster than it can be reabsorbed. The result is ascites: liters of fluid trapped in the peritoneal space. RAAS overactivation is now considered the hallmark of this sodium-retaining process, which is exactly why aldosterone-blocking diuretics sit at the center of treatment.4PubMed Central. Activation of RAAS in a rat model of liver cirrhosis: no effect of losartan on renal sodium excretion
The Standard Diuretic Regimen
Spironolactone is the backbone of ascites treatment. It blocks aldosterone receptors in the kidney, counteracting the very hormone that drives sodium retention in cirrhosis. By preventing sodium from being reabsorbed in the distal tubule and collecting duct, spironolactone allows the kidneys to let go of sodium and, with it, water. Furosemide is the usual partner drug. It works further upstream in the kidney at a different segment of the tubule, blocking sodium reabsorption through a separate channel. Together, they attack sodium retention from two angles.
The typical starting combination is spironolactone at 100 mg per day and furosemide at 40 mg per day, often described as a 100:40 ratio. Both can be increased in tandem if the patient isn’t losing enough fluid. Maximum doses generally reach 400 mg of spironolactone and 160 mg of furosemide daily, though side effects often limit how high you can go.
Combined Versus Step-Up Approaches
There has been a long-running debate over whether to start both drugs simultaneously or begin with spironolactone alone and add furosemide only if the patient doesn’t respond. A randomized trial comparing these two strategies in patients with moderate ascites and no kidney failure found that the combined approach won out. Adverse effects were significantly more frequent when spironolactone was given alone first and furosemide added later: about 38% of sequential-therapy patients developed side effects versus 20% in the combined group. High potassium levels were the most common problem in the step-up arm. Perhaps most telling, a higher proportion of patients on combined therapy resolved their ascites without needing to change their diuretic dose.5PubMed. Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial
That said, a separate trial showed that spironolactone alone achieved a response rate comparable to the combination (about 94% versus 98%), with a similar complication profile. The key difference was practical: patients on spironolactone alone needed their dose adjusted far more often, nearly twice as frequently as those on the combination.6PubMed. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis For outpatient management, where fewer clinic visits is a real advantage, starting both drugs together tends to be the more practical choice. Current guidelines from the British Society of Gastroenterology endorse combined therapy as the preferred approach for moderate ascites.7PubMed. Guidelines on the management of ascites in cirrhosis
Why Sodium Restriction Matters Alongside Diuretics
Diuretics work by making the kidneys excrete more sodium than they otherwise would. But if a patient is eating large amounts of salt, the kidneys may simply be pushed to retain what the diuretic is trying to flush out, turning it into a tug-of-war. Sodium restriction to roughly 80 to 90 mmol per day (about 2 grams of sodium, or around 5 grams of table salt) significantly shortens the time it takes for ascites to disappear when diuretics are used.8Hepatology. Dietary sodium restriction during diuresis of ascites
The trouble is that adherence to a low-salt diet is remarkably poor. A cross-sectional study of outpatients with cirrhotic ascites found that only about 31% actually followed a moderately low-salt diet. Strikingly, more than half of the non-adherent patients believed they were following it. Those who did comply averaged around 80 mmol of sodium per day, while those who didn’t averaged over 200 mmol, more than double. The catch: adherent patients also ate about 20% fewer calories, raising concerns about nutritional adequacy if sodium restriction is pursued too aggressively.9PubMed. Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: a real-life cross-sectional study Patients in structured care management programs were more likely to stick with the diet, suggesting that regular follow-up and dietary counseling make a meaningful difference.
Monitoring and Safe Rates of Fluid Loss
Diuretics in cirrhosis cannot be managed on autopilot. Guidelines recommend that weight loss from diuretics should not exceed half a kilogram per day in patients who have ascites alone, and no more than one kilogram per day in those who also have swelling in the legs. The reason is that fluid in the abdomen can only be reabsorbed into the bloodstream at a limited rate. Push diuretics too hard and you don’t drain the belly faster; instead, you shrink the blood volume, dropping blood pressure and harming the kidneys.10PubMed. Guidelines on the management of ascites in cirrhosis – Section: Diuretics
Regular blood tests are essential after starting or adjusting diuretics. Clinicians typically monitor kidney function, sodium, and potassium levels within the first week and then at intervals as doses stabilize. Nearly half of patients who develop adverse effects from diuretics end up needing a dose reduction or discontinuation altogether.10PubMed. Guidelines on the management of ascites in cirrhosis – Section: Diuretics
Complications That Diuretics Can Trigger
The most common side effects of diuretic therapy in cirrhosis are electrolyte disturbances, kidney injury, and hepatic encephalopathy. Spironolactone raises potassium levels (since it blocks aldosterone, which normally promotes potassium excretion), while furosemide lowers them. In theory, combining the two balances potassium shifts, but in practice, potassium can still swing in either direction, especially when doses are being adjusted.
Low potassium is particularly dangerous in cirrhosis because it can contribute to hepatic encephalopathy, the confusion and cognitive impairment that occurs when the brain is exposed to excess ammonia. When potassium drops, ammonia enters the central nervous system more readily. Lower potassium lets ammonium ions compete more successfully for potassium transporters across the blood-brain barrier, and the metabolic alkalosis that accompanies low potassium converts more ammonia into its gaseous form, which crosses the barrier freely.11PubMed. Hypokalaemia – an active contributor to hepatic encephalopathy? This is one reason why furosemide, a potent potassium-wasting drug, is rarely used alone in cirrhotic ascites.
Kidney injury is another constant concern. In patients with cirrhosis who develop kidney problems, prerenal failure (from volume depletion) accounts for about 70% of cases, while the remaining 30% is hepatorenal syndrome, which carries a worse prognosis. Overly aggressive diuretic dosing can tip a patient into either scenario, which is why the weight-loss limits mentioned above exist and why kidney function is tracked closely throughout treatment.
Why Cirrhosis Changes How Diuretics Behave
A drug doesn’t necessarily work the same way in a cirrhotic liver as it does in a healthy one. Furosemide, for example, maintains roughly the same blood levels in cirrhosis as in healthy people, but the kidneys respond differently to it. Studies in cirrhotic patients show a significant drop in urine sodium output and volume compared to healthy volunteers given the same dose, even though the drug reaches the kidney tubule in similar concentrations. The tubule itself appears less sensitive to furosemide’s effects.12PubMed. Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide In patients with advanced, diuretic-resistant ascites, the pharmacokinetics and pharmacodynamics of both furosemide and torasemide (a related loop diuretic) are markedly altered.13PubMed. Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites
This blunted response helps explain why some patients need high diuretic doses and why others eventually stop responding altogether. The problem isn’t always that the drug can’t get to the kidney; it’s that the kidney, under the influence of cirrhosis-driven hormonal and hemodynamic changes, refuses to cooperate fully.
When Diuretics Stop Working
Refractory ascites is formally defined as ascites that cannot be mobilized, or that recurs rapidly after drainage, despite maximum tolerated diuretic therapy and sodium restriction. It comes in two forms: diuretic-resistant ascites, where the fluid simply won’t respond to full-dose treatment, and diuretic-intolerant ascites, where side effects like kidney injury, encephalopathy, or severe electrolyte imbalances prevent escalation to effective doses.14Clinical and Molecular Hepatology. Management of refractory ascites – Section: DEFINITION OF RA Before making this diagnosis, clinicians must rule out other culprits for worsening fluid retention, including portal vein blood clots, hidden infections, cancer, and non-compliance with medications or diet.15PubMed Central. Evaluation and management of patients with refractory ascites
Once ascites is truly refractory, diuretics alone are no longer the primary tool. The management shifts to repeated large-volume paracentesis (draining liters of fluid with a needle) or, in selected patients, placement of a transjugular intrahepatic portosystemic shunt (TIPS). Liver transplant evaluation should also be on the table, since refractory ascites signals advanced liver disease with a limited prognosis.
Albumin Infusion During Large-Volume Drainage
When more than about five liters of ascitic fluid are drained at once, the sudden shift in abdominal pressure can trigger a drop in effective blood volume, a complication known as post-paracentesis circulatory dysfunction. This isn’t just uncomfortable; it can worsen kidney function and increase mortality risk. Albumin infusion during the procedure substantially reduces that risk. A meta-analysis of randomized trials found that albumin cut the odds of post-paracentesis circulatory dysfunction compared to no treatment, and it outperformed every alternative volume expander tested, including dextran, gelatin, and hydroxyethyl starch.16PubMed. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials For this reason, albumin is the standard-of-care replacement fluid during large-volume paracentesis, typically given at a dose of 6 to 8 grams per liter of fluid removed.
TIPS and Its Effect on Kidney Function
TIPS creates a channel inside the liver that diverts blood from the high-pressure portal vein directly into the hepatic vein, reducing portal pressure. By lowering that pressure, it tackles one of the root causes of ascites rather than just chasing the symptoms with diuretics. One of its less discussed benefits is its effect on the kidneys. In patients with refractory ascites, TIPS dramatically increased urinary sodium excretion within seven days, with some patients seeing their sodium output jump to over four times their baseline.17PubMed. Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites This improvement in renal sodium handling is what allows many post-TIPS patients to reduce or even discontinue their diuretics.
The kidney benefits appear most pronounced in patients whose kidney function was already impaired. A matched cohort analysis found that patients with a baseline kidney filtration rate below 60 mL/min who received TIPS had a significant improvement in kidney function compared to those managed with repeated paracentesis alone, a gain of about 21 mL/min after adjustment.18PubMed Central. Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis In patients with preserved kidney function, TIPS didn’t add measurable benefit over paracentesis in that regard. TIPS is not without risks, though. It can precipitate hepatic encephalopathy and is contraindicated in patients with severe liver failure, making careful patient selection critical.
SGLT2 Inhibitors as an Emerging Option
An intriguing new avenue involves SGLT2 inhibitors, a class of drugs originally developed for type 2 diabetes. These drugs block sodium and glucose reabsorption in the proximal kidney tubule, an entirely different site from where spironolactone or furosemide act. This means they promote sodium loss and osmotic water excretion through a mechanism that doesn’t overlap with conventional diuretics.19PubMed Central. The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review Beyond simple diuresis, they may also dampen RAAS activation and improve metabolic parameters in cirrhosis.
A pilot study of dapagliflozin (one of the SGLT2 inhibitors) in patients with recurrent ascites found significantly better ascites control at six months compared to standard care, along with a marked increase in urinary sodium excretion. However, the results came with a serious caveat: patients on dapagliflozin had significantly higher rates of acute kidney injury (50% versus 15%) and infections (55% versus 20%).20PubMed. Safety and Efficacy of Dapagliflozin in Recurrent Ascites: A Pilot Study Survival at six months was similar between groups. These early results are enough to justify further study but nowhere near enough to recommend routine use. Patients with cirrhosis are already vulnerable to infections and kidney problems, and adding a drug that worsens both needs careful justification.
When the Cause of Ascites Is Not Cirrhosis
Not all ascites is cirrhotic, and the cause determines whether diuretics will do much good. This distinction matters because clinicians sometimes default to diuretic therapy without considering the underlying mechanism. In malignant ascites caused by cancer, diuretic effectiveness depends heavily on where the cancer is and how it’s producing fluid. A study examining different types of malignant ascites found that patients whose ascites was caused by massive liver metastases lost weight and drained fluid effectively with diuretics, at a rate comparable to what you’d see in cirrhotic patients. But patients with peritoneal carcinomatosis, where cancer cells coat the abdominal lining, showed essentially no mobilization of ascites despite losing weight. The weight they lost came from other fluid compartments, not the belly. Patients with chylous malignant ascites (caused by lymphatic obstruction) fared similarly poorly. Worse, some of these patients developed kidney dysfunction or dangerously low blood pressure from the diuretics, making the treatment not only ineffective but harmful.21Gastroenterology. Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics
The takeaway for patients and clinicians is straightforward: before committing to diuretic therapy, you need to know why the fluid is there. In peritoneal carcinomatosis, paracentesis for symptom relief is typically the better approach, and diuretics risk doing more harm than good.
Ascites Management in Veterinary Medicine
The basic principles of ascites management extend beyond human medicine. Dogs with ascites from cardiac disease, for instance, respond well to a combination of diuretics with pimobendan (a heart medication) and ACE inhibitors, an approach that parallels human heart-failure management. Dogs with cirrhosis and portal hypertension are treated with diuretics alongside carvedilol, amino acid supplementation, and liver-supportive drugs, a multimodal regimen that reflects the same logic used in human cirrhotic ascites: address the portal pressure, support the failing liver, and use diuretics to control fluid.22Journal of Veterinary and Animal Sciences. Multimodal assessment and management of ascites in dogs: A study on clinical parameters, laboratory findings, imaging features and therapeutic response The pharmacology differs in the specifics, but the underlying principle holds across species: diuretics are a tool for managing the fluid, not for treating the diseased organ that caused it.